Source-grounded facts extracted from Disc Medicine, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Disc Medicine, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $63.5 million for the three months ended March 31, 2026.
“On May 5, 2026, Disc Medicine, Inc. announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.”
Disc Medicine, Inc. announced a restructuring with charges of approximately $2.0 million affecting commercial functions and certain supporting functions (approximately 20%).
“Company expects to complete the implementation of the Restructuring Plan in the second quarter of 2026. The Company expects that it will incur aggregate charges of approximately $2.0 million in connection with the Restructuring Plan, consisting primarily of severance costs, which will be recorded primarily in the first quarter of 2026. The costs that the Company”
Disc Medicine, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $26.9 million.
“Disc Medicine, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
Disc Medicine, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $76.4 million.
“Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.